Welcome to the 1st annual
CNS Clinical Trials conference

 


Tuesday 2 and Wednesday 3 June 2009, Brussels, Belgium
 

Neurological   disorders  and  Central  Nervous  System (CNS) diseases  are  reported  to  account  for  one third  of the  world's  disease  burden. Due to the correlation with the aging population and these diseases this statistic is projected to increase rapidly in the coming years. As such, the market for CNS drugs was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007.

However, clinical  trials for  Neurological  disorders  are very  complex compared to  most  therapeutic areas with many additional challenges such as recruiting  mentally  unstable  subjects  and understanding their pain response.

Through extensive research with industry experts, VIBpharma’s CNS Clinical Trials conference reveals how to tackle such issues. A series of case study based presentations and interactive discussions will cover key priorities such as accelerating and improving patient recruitment and retention, bridging the gap between pre-clinical and clinical CNS trials, optimising CNS trial design and management, utilising emerging technologies to monitor the clinical drug effect, designing effective adaptive trials in CNS.

Password: